Neurocrine Biosciences (NBIX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.85
- Estimate
- $1.96
- Surprise
- +45.4%
- Revenue (period 2026-06-30)
- $959.0M
- Score at report (before → after)
- 7.2 → 7.2/10
Revenue source: xbrl.
How the report landed
Neurocrine Biosciences (NBIX) beat the $1.96 estimate with adjusted EPS of $2.85 — a large 45.4% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.2/10) to Hold at 7.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NBIX Buy (Wait) at 7.3/10.
3 of the last 4 quarters beat the estimate; this quarter's +45.4% surprise compares with a +11.6% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: INGREZZA
- Earnings in 4 days (event risk)
- Below 200-MA (30d, -0.6%)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $146.52
- Entry target
- $142.56
- Price target
- $185.60
- Stop
- $136.06
- Upside to target
- +26.7%
- Reward-to-risk
- 2.7:1
The stock trades at 21.3× trailing but 12.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
NBIX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $14.79B
- P/E (fwd)
- 12.2
- P/E (ttm)
- 21.3
- 52-week range
- $122.14–$186.12
- Off 52-week high
- 21.3%
- RSI (14)
- 58
- Volume vs avg
- 0.09×
- Score today
- 7.3/10